MedPath
HSA Approval

NUROFEN TABLET 400MG

SIN14587P

NUROFEN TABLET 400MG

NUROFEN TABLET 400MG

August 13, 2014

RECKITT BENCKISER (SINGAPORE) PTE LTD

RECKITT BENCKISER (SINGAPORE) PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantRECKITT BENCKISER (SINGAPORE) PTE LTD
Licence HolderRECKITT BENCKISER (SINGAPORE) PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

TABLET, SUGAR COATED

**Recommended Dose** For oral administration and short-term use only. During short-term use, if symptoms persist or worsen, the patient should be advised to consult a doctor. Adult and children over 12 years: The minimum effective dose should be used for the shortest time necessary to relieve symptoms. If the product is required for more than 10 days or if the symptoms worsen, the patient should consult a doctor. Take 1 tablet with water, up to three times a day as required. Leave at least four hours between doses. Do not take more than 3 tablets in any 24 hour period. Not for use by children under 12 years of age.

ORAL

Medical Information

**Indications** Nurofen relieves pain such as headache, migraine, dental pain, period pain, rheumatic pain, muscular pain and backache. Nurofen relieves fever such as fever associated with cold and flu.

**Contraindication** Hypersensitivity to ibuprofen or any of the excipients in the product. Patients who have previously shown hypersensitivity reactions (e.g. asthma, rhinitis, angioedema, or urticaria) in response to aspirin or other non-steroidal anti-inflammatory drugs. Active or history of recurrent peptic ulcer/haemorrhage (two or more distinct episodes of proven ulceration or bleeding). History of gastrointestinal bleeding or perforation, related to previous NSAIDs therapy. Severe heart failure, renal failure or hepatic failure (see Special warning and precaution for use – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). In patients who have recently undergone coronary artery bypass graft (CABG) surgery and revascularization procedures. Last trimester of pregnancy (see Pregnancy and lactation – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_).

M01AE01

ibuprofen

Manufacturer Information

RECKITT BENCKISER (SINGAPORE) PTE LTD

RECKITT BENCKISER HEALTHCARE INTERNATIONAL LIMITED

Active Ingredients

Ibuprofen

400mg

Ibuprofen

Documents

Package Inserts

Nurofen Tablet 400mg PI.pdf

Approved: October 18, 2021

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

NUROFEN TABLET 400MG - HSA Approval | MedPath